相似文献
1
The shifting treatment paradigm of metastatic renal cell carcinoma.
Nat Rev Urol. 2022 Nov;19(11):631-632. doi: 10.1038/s41585-022-00651-9.
2
Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Ann Oncol. 2011 May;22(5):1243. doi: 10.1093/annonc/mdr132.
3
Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Ann Oncol. 2011 May;22(5):995-996. doi: 10.1093/annonc/mdq654. Epub 2011 Jan 28.
4
The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
J Urol. 2011 Jan;185(1):54-9. doi: 10.1016/j.juro.2010.09.018. Epub 2010 Nov 12.
5
Are we really making an advance in the treatment of metastatic renal cell carcinoma?
Eur Urol. 2006 Apr;49(4):604-5. doi: 10.1016/j.eururo.2006.01.039. Epub 2006 Feb 6.
6
Long-term treatment of metastatic renal-cell carcinoma with fluorouracil.
Lancet Oncol. 2004 Nov;5(11):690-2. doi: 10.1016/S1470-2045(04)01611-0.
7
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
8
Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Expert Rev Anticancer Ther. 2006 Aug;6(8):1295-304. doi: 10.1586/14737140.6.8.1295.
9
The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Hematol Oncol Clin North Am. 2011 Aug;25(4):753-64. doi: 10.1016/j.hoc.2011.05.002.
10
High-dose interleukin-2 in metastatic renal cell carcinoma.
J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9. doi: 10.1200/JCO.2005.02.1709.
引用本文的文献
1
The prognostic and immune significance of in clear cell renal cell carcinoma.
Transl Cancer Res. 2025 Feb 28;14(2):1008-1023. doi: 10.21037/tcr-24-1509. Epub 2025 Feb 26.
2
Cytoreductive Nephrectomy Following Immunotherapy for Metastatic Renal Cell Carcinoma and IVC Tumor Thrombus Arising from a Horseshoe Kidney.
Kidney Cancer J. 2024 Jun;22(2):46-52.
3
Prognostic biomarker CPEB3 and its associations with immune infiltration in clear cell renal cell carcinoma.
Biomed Rep. 2024 Feb 19;20(4):63. doi: 10.3892/br.2024.1751. eCollection 2024 Apr.
本文引用的文献
1
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001.
2
Novel emerging biomarkers to immunotherapy in kidney cancer.
Ther Adv Med Oncol. 2021 Nov 25;13:17588359211059367. doi: 10.1177/17588359211059367. eCollection 2021.
3
Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges.
JCO Oncol Pract. 2022 Mar;18(3):197-199. doi: 10.1200/OP.21.00446. Epub 2021 Sep 22.
4
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Cancer Treat Rev. 2021 Sep;99:102239. doi: 10.1016/j.ctrv.2021.102239. Epub 2021 Jun 1.
5
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
6
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
7
Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214. doi: 10.1038/s41571-020-00455-z. Epub 2021 Jan 12.
8
Targeting the HIF2-VEGF axis in renal cell carcinoma.
Nat Med. 2020 Oct;26(10):1519-1530. doi: 10.1038/s41591-020-1093-z. Epub 2020 Oct 5.
9
Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence.
JAMA Netw Open. 2019 Oct 2;2(10):e1912869. doi: 10.1001/jamanetworkopen.2019.12869.
10
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
N Engl J Med. 2017 Jan 26;376(4):354-366. doi: 10.1056/NEJMra1601333.
Zotero 插件